Von Hippel-Lindau Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Von Hippel-Lindau disease markets are expected to exhibit a CAGR of 7.97% during 2024-2034.
The Von Hippel-Lindau disease market has been comprehensively analyzed in IMARC's new report titled "Von Hippel-Lindau Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Von Hippel-Lindau disease (VHL) refers to a rare genetic disorder that affects the growth of tumors and cysts in different parts of the body. It is caused by mutations in the VHL gene, which provides instructions for making a protein that helps to regulate cell growth and division. When this gene is mutated, it can lead to the development of abnormal growth in various organs, such as the eyes, brain, spinal cord, kidneys, pancreas, and adrenal glands. The common indications associated with this condition include headaches, hearing loss or ringing in the ears, high blood pressure, impaired balance, loss of muscle strength or coordination, vomiting, nausea, abdominal pain, vision problems, etc. Diagnosing this ailment is typically based on a review of the patient’s medical history and clinical features. Genetic testing that identifies changes in chromosomes, genes, or proteins is also recommended among the population. The healthcare provider may further adopt diagnostic procedures, like magnetic resonance imaging (MRI) and computed tomography (CT) scans, to examine the affected site and confirm a diagnosis.
The increasing prevalence of hereditary conditions that produce DNA abnormalities and uncontrolled growth of harmful cells in the body is primarily driving the Von Hippel-Lindau disease market. In addition to this, the escalating application of exome sequencing tests, which can detect genetic variations associated with birth defects and developmental delays, thereby providing an accurate diagnosis in patients, is also augmenting the market growth. Furthermore, the widespread adoption of stereotactic radiation therapy, since it delivers an adequate amount of radiation to the tumor in a shorter period of time than other traditional treatments, is creating a positive outlook for the market. Additionally, the rising demand for hypoxia-inducible factor-2 alpha inhibitor that works by declining transcription and expression of target genes related to angiogenesis, cellular proliferation, and tumor progression, is acting as another significant growth-inducing factor. Besides this, the emerging popularity of cryotherapy for treating advanced conditions, since it can fully obliterate the tumor and promote overall survival, is expected to drive the Von Hippel-Lindau disease market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Von Hippel-Lindau disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Von Hippel-Lindau disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Von Hippel-Lindau disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Von Hippel-Lindau disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Von Hippel-Lindau disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Von Hippel-Lindau disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Von Hippel-Lindau disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Von Hippel-Lindau disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Von Hippel-Lindau disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Von Hippel-Lindau disease across the seven major markets?
What is the size of the Von Hippel-Lindau disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Von Hippel-Lindau disease?
What will be the growth rate of patients across the seven major markets?
Von Hippel-Lindau Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Von Hippel-Lindau disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Von Hippel-Lindau disease market?
What are the key regulatory events related to the Von Hippel-Lindau disease market?
What is the structure of clinical trial landscape by status related to the Von Hippel-Lindau disease market?
What is the structure of clinical trial landscape by phase related to the Von Hippel-Lindau disease market?
What is the structure of clinical trial landscape by route of administration related to the Von Hippel-Lindau disease market?
The Von Hippel-Lindau disease market has been comprehensively analyzed in IMARC's new report titled "Von Hippel-Lindau Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Von Hippel-Lindau disease (VHL) refers to a rare genetic disorder that affects the growth of tumors and cysts in different parts of the body. It is caused by mutations in the VHL gene, which provides instructions for making a protein that helps to regulate cell growth and division. When this gene is mutated, it can lead to the development of abnormal growth in various organs, such as the eyes, brain, spinal cord, kidneys, pancreas, and adrenal glands. The common indications associated with this condition include headaches, hearing loss or ringing in the ears, high blood pressure, impaired balance, loss of muscle strength or coordination, vomiting, nausea, abdominal pain, vision problems, etc. Diagnosing this ailment is typically based on a review of the patient’s medical history and clinical features. Genetic testing that identifies changes in chromosomes, genes, or proteins is also recommended among the population. The healthcare provider may further adopt diagnostic procedures, like magnetic resonance imaging (MRI) and computed tomography (CT) scans, to examine the affected site and confirm a diagnosis.
The increasing prevalence of hereditary conditions that produce DNA abnormalities and uncontrolled growth of harmful cells in the body is primarily driving the Von Hippel-Lindau disease market. In addition to this, the escalating application of exome sequencing tests, which can detect genetic variations associated with birth defects and developmental delays, thereby providing an accurate diagnosis in patients, is also augmenting the market growth. Furthermore, the widespread adoption of stereotactic radiation therapy, since it delivers an adequate amount of radiation to the tumor in a shorter period of time than other traditional treatments, is creating a positive outlook for the market. Additionally, the rising demand for hypoxia-inducible factor-2 alpha inhibitor that works by declining transcription and expression of target genes related to angiogenesis, cellular proliferation, and tumor progression, is acting as another significant growth-inducing factor. Besides this, the emerging popularity of cryotherapy for treating advanced conditions, since it can fully obliterate the tumor and promote overall survival, is expected to drive the Von Hippel-Lindau disease market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Von Hippel-Lindau disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Von Hippel-Lindau disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Von Hippel-Lindau disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Von Hippel-Lindau disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Von Hippel-Lindau disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Von Hippel-Lindau disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Von Hippel-Lindau disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Von Hippel-Lindau disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Von Hippel-Lindau disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Von Hippel-Lindau disease across the seven major markets?
What is the size of the Von Hippel-Lindau disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Von Hippel-Lindau disease?
What will be the growth rate of patients across the seven major markets?
Von Hippel-Lindau Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Von Hippel-Lindau disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Von Hippel-Lindau disease market?
What are the key regulatory events related to the Von Hippel-Lindau disease market?
What is the structure of clinical trial landscape by status related to the Von Hippel-Lindau disease market?
What is the structure of clinical trial landscape by phase related to the Von Hippel-Lindau disease market?
What is the structure of clinical trial landscape by route of administration related to the Von Hippel-Lindau disease market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VON HIPPEL-LINDAU DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VON HIPPEL-LINDAU DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VON HIPPEL-LINDAU DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 VON HIPPEL-LINDAU DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VON HIPPEL-LINDAU DISEASE - UNMET NEEDS
10 VON HIPPEL-LINDAU DISEASE - KEY ENDPOINTS OF TREATMENT
11 VON HIPPEL-LINDAU DISEASE - MARKETED PRODUCTS
11.1 List of Von Hippel-Lindau Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Belzutifan - Peloton Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 VON HIPPEL-LINDAU DISEASE - PIPELINE DRUGS
12.1 List of Von Hippel-Lindau Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. VON HIPPEL-LINDAU DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VON HIPPEL-LINDAU DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VON HIPPEL-LINDAU DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Von Hippel-Lindau Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Von Hippel-Lindau Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Von Hippel-Lindau Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Von Hippel-Lindau Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Von Hippel-Lindau Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Von Hippel-Lindau Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Von Hippel-Lindau Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Von Hippel-Lindau Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
16 VON HIPPEL-LINDAU DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VON HIPPEL-LINDAU DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VON HIPPEL-LINDAU DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 VON HIPPEL-LINDAU DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 VON HIPPEL-LINDAU DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 VON HIPPEL-LINDAU DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 VON HIPPEL-LINDAU DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 VON HIPPEL-LINDAU DISEASE - UNMET NEEDS
10 VON HIPPEL-LINDAU DISEASE - KEY ENDPOINTS OF TREATMENT
11 VON HIPPEL-LINDAU DISEASE - MARKETED PRODUCTS
11.1 List of Von Hippel-Lindau Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Belzutifan - Peloton Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 VON HIPPEL-LINDAU DISEASE - PIPELINE DRUGS
12.1 List of Von Hippel-Lindau Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. VON HIPPEL-LINDAU DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. VON HIPPEL-LINDAU DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 VON HIPPEL-LINDAU DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Von Hippel-Lindau Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Von Hippel-Lindau Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Von Hippel-Lindau Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Von Hippel-Lindau Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Von Hippel-Lindau Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Von Hippel-Lindau Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Von Hippel-Lindau Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Von Hippel-Lindau Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Von Hippel-Lindau Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Von Hippel-Lindau Disease - Access and Reimbursement Overview
16 VON HIPPEL-LINDAU DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 VON HIPPEL-LINDAU DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 VON HIPPEL-LINDAU DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
